AETHLON MEDICAL, INC. Revenue from Contract with Customer, Excluding Assessed Tax
AETHLON MEDICAL, INC. (AEMD) reported Revenue from Contract with Customer, Excluding Assessed Tax of $0 for the 12-month period ending 2024-03-31, per its 10-K filed 2024-06-27.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2024-06-27
- AETHLON MEDICAL, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-03-31 was $574.25K, a 4278.20% increase year-over-year.
- AETHLON MEDICAL, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- AETHLON MEDICAL, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- AETHLON MEDICAL, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- AETHLON MEDICAL, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- AETHLON MEDICAL, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $574.25K, a 95.21% increase from fiscal 2022.
- AETHLON MEDICAL, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $294.17K, a 55.37% decline from fiscal 2021.
- AETHLON MEDICAL, INC. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $659.10K, a 1.37% increase from fiscal 2020.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-K · filed 2024-06-27 | |||
| 2023-03-31 | $574.25K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-27 | $574.25K derived: sum of 2 quarters · filed 2024-06-27 | $574.25K derived: sum of 3 quarters · filed 2024-06-27 | $574.25K 10-K · filed 2024-06-27 |
| 2022-12-31 | $0.00 10-Q · filed 2023-02-13 | $0.00 derived: sum of 2 quarters · filed 2023-02-13 | $0.00 10-Q · filed 2023-02-13 | $13.12K derived: sum of 4 quarters · filed 2023-06-28 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | $13.12K derived: sum of 3 quarters · filed 2023-06-28 | $30.23K derived: sum of 4 quarters · filed 2023-06-28 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 | $13.12K derived: sum of 2 quarters · filed 2023-06-28 | $30.23K derived: sum of 3 quarters · filed 2023-06-28 | $162.20K derived: sum of 4 quarters · filed 2023-06-28 |
| 2022-03-31 | $13.12K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $30.23K derived: sum of 2 quarters · filed 2023-06-28 | $162.20K derived: sum of 3 quarters · filed 2023-06-28 | $294.17K 10-K · filed 2023-06-28 |
| 2021-12-31 | $17.12K 10-Q · filed 2023-02-13 | $149.08K derived: sum of 2 quarters · filed 2023-02-13 | $281.05K 10-Q · filed 2023-02-13 | |
| 2021-09-30 | $131.97K 10-Q · filed 2022-11-14 | $263.93K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $131.97K 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $659.10K 10-K · filed 2022-06-28 | |||
| 2020-03-31 | $650.19K 10-K · filed 2021-06-24 | |||
| 2019-03-31 | $229.63K 10-K · filed 2020-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |